NASDAQ: UBXUnity Biotechnology Inc Stock
$1.13+0.12 (+11.88%)
Updated Apr 30, 2025
UBX Price
$1.13
Fair Value Price
-$0.72
Market Cap
$19.45M
52 Week Low
$0.85
52 Week High
$3.10
P/E
-0.7x
P/B
-94.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-149.03
Operating Cash Flow
-$22M
Beta
1.22
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
UBX Overview
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UBX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
UBX
Ranked#396 of 462
Ranked#396 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important UBX news, forecast changes, insider trades & much more!
UBX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UBX ($1.13) is overvalued by 256.77% relative to our estimate of its Fair Value price of -$0.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UBX ($1.13) is not significantly undervalued (256.77%) relative to our estimate of its Fair Value price of -$0.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UBX due diligence checks available for Premium users.
Valuation
UBX fair value
Fair Value of UBX stock based on Discounted Cash Flow (DCF)
Price
$1.13
Fair Value
-$0.72
Undervalued by
256.77%
UBX ($1.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UBX ($1.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
-162.28x
Market
29.18x
UBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-94.88x
Industry
4.45x
UBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.3M
Profit Margin
0%
UBX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$30.3M
Liabilities
$30.6M
Debt to equity
-149.03
UBX's short-term assets ($17.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UBX's long-term liabilities ($21.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UBX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
UBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.4M
Investing
$6.8M
Financing
$0.0
UBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UBX vs Biotech Stocks
Unity Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.